“…Its expression is frequently altered by disharmony or mutation in cancer, and these changes contribute to genomic instability and cancer progression [ 11 ]. FEN1 is highly expressed in a variety of tumors, including prostate cancer, neuroblastoma, pancreatic and breast cancer, lung cancer, testicular cancer, glioblastoma, and astrocytoma and so on [ 51 , 52 , 53 , 54 , 55 ]. The expression of FEN1 in different tumors and healthy tissues obtained from the TGCA database is shown in Figure 4 .…”